SCR-LIP-000556 · Claim · machine-readable JSON →

This narrative review describes estrogen pathway dysregulation in lipedema, with an increased ER-alpha/ER-beta ratio in affected lower-body subcutaneous adipose tissue, local upregulation of aromatase CYP19A1, and estrogen-induced ZNF423 promoting preadipocyte differentiation via PPARG, alongside AKR1C1 mutations raising progesterone and stimulating adipogenesis.

This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
very low (GRADE)
Evidence
1 source(s)
Dates
2026-11-17 → 2026-11-17

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17

Evidence over time

2026Lipedema: pathophysiological insights and therapeutic strategies — An update for dermatologists (2026) · consistent

Evidence (1)

Context (PECO)

Populationwomen with lipedema (narrative review)
Conditionlipedema
Exposurehormonal factors (estrogen pathway, progesterone-related gene variants)
Comparatorunaffected adipose tissue/controls
Outcomeadipose tissue gene expression and adipogenesis in lipedema
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log